ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma

Cancer Cytopathology

Volumn 123, Issue 4, 2015, Pages 253-257

  Nagymanyoki, Zoltan ^a   Mutter, George L ^a   Hornick, Jason L ^a   Cibas, Edmund S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ARID1A (AT rich interactive domain 1A gene); cytology; endometrial carcinoma; immunohistochemistry; peritoneal washing

Indexed keywords

AT RICH INTERACTIVE DOMAIN 1A PROTEIN; TRANSCRIPTION FACTOR PAX8; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; ARTICLE; ASCITES FLUID CYTOLOGY; AT RICH INTERACTIVE DOMAIN 1A GENE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; COMPARATIVE STUDY; CYTODIAGNOSIS; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIAL NEOPLASMS; EVALUATION STUDY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

CYTODIAGNOSIS; CYTOLOGICAL TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; ENDOMETRIOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NUCLEAR PROTEINS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84934760403     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21514     Document Type: Article

References (24)

1. Sif S, Saurin AJ, Imbalzano AN, Kingston RE,. Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev. 2001; 15: 603-618.
2. Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree GR,. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev. 1996; 10: 2117-2130.
3. Reisman D, Glaros S, Thompson EA,. The SWI/SNF complex and cancer. Oncogene. 2009; 28: 1653-1668.
4. Wiegand KC, Shah SP, Al-Agha OM, et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363: 1532-1543.
5. Maeda D, Mao TL, Fukayama M, et al., Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci. 2010; 11: 5120-5128.
6. Guan B, Mao TL, Panuganti PK, et al., Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011; 35: 625-632.
7. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O,. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012; 25: 615-624.
8. Ayhan A, Mao TL, Seckin T, et al., Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012; 22: 1310-1315.
9. Keetel WC, Elkins HB,. Experience with radioactive colloidal gold in the treatment of ovarian carcinoma. Am J Obstet Gynecol. 1956; 71: 553-568.
10. Keetel WC, Pixley EE, Buchsbaum HJ,. Experience with peritoneal cytology in the management of gynecologic malignancies. Am J Obstet Gynecol. 1974; 120: 174-182.
11. Creasman WT, Rutledge F,. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol. 1971; 110: 773-781.
12. McLellan R, Dillon MB, Currie JL, Rosenshein NB,. Peritoneal cytology in endometrial cancer: a review. Obstet Gynecol Surv. 1989; 44: 711-719.
13. Harouny VR, Sutton GP, Clark SA, Geisler HE, Stehman FB, Erlich CE,. The importance of peritoneal cytology in endometrial carcinoma. Obstet Gynecol. 1988; 72: 394-398.
14. Creasman WT, DiSaia PJ, Blessing J, Wilkinson RH, Johnston W, Weed JC,. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol. 1981; 141: 921-929.
15. Mazurka JL, Krepart GV, Lotocki RJ,. Prognostic significance of positive peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol. 1998; 158: 303-306.
16. Turner DA, Gershenson DM, Atkinson N, Sneige N, Wharton AT,. The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol. 1989; 74: 775-780.
17. Morrow CP, Bundy BN, Kurman RJ, et al., Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991; 40: 55-65.
18. Grimshaw RN, Tupper WC, Fraser RC, Tompkins MG, Jeffrey JF,. Prognostic value of peritoneal cytology in endometrial carcinoma. Gynecol Oncol. 1990; 36: 97-100.
19. Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS,. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol. 1991; 78: 63-69.
20. Konski A, Poulter C, Keys H, Rubin P, Beecham J, Doane K,. Absence of prognostic significance, peritoneal dissemination and treatment advantage in endometrial cancer patients with positive peritoneal cytology. Int J Radiat Oncol Biol Phys. 1988; 4: 49-55.
21. Kadar N, Homesley HD, Malfetano JH,. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol. 1992; 46: 145-149.
22. Pecorelli S,. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105: 103-104.
23. Creasman W,. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009; 105: 109.
24. Wilentz RE, Su GH, Dai JL, et al., Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol. 2000; 156: 37-43.